A detailed history of Orbimed Advisors LLC transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 15,219,994 shares of CMPX stock, worth $52.4 Million. This represents 1.41% of its overall portfolio holdings.

Number of Shares
15,219,994
Previous 22,362,850 31.94%
Holding current value
$52.4 Million
Previous $42.5 Million 6.87%
% of portfolio
1.41%
Previous 1.32%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$1.46 - $2.69 $10.4 Million - $19.2 Million
-7,142,856 Reduced 31.94%
15,219,994 $39.6 Million
Q4 2022

Feb 14, 2023

BUY
$2.55 - $5.41 $1.03 Million - $2.17 Million
402,000 Added 1.83%
22,362,850 $112 Million
Q2 2022

Aug 15, 2022

BUY
$1.43 - $3.1 $454,561 - $985,412
317,875 Added 1.47%
21,960,850 $58.2 Million
Q4 2021

Feb 14, 2022

BUY
$2.88 - $3.98 $62.3 Million - $86.1 Million
21,642,975 New
21,642,975 $68.6 Million

Others Institutions Holding CMPX

About Compass Therapeutics, Inc.


  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $348M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.